問卷

TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Digestive System Department

Division of Radiation Therapy

Division of Hematology & Oncology

Division of General Internal Medicine

Chiayi Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of General Internal Medicine

Digestive System Department

更新時間:2023-09-19

盧勝男
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

62Cases

2022-01-01 - 2026-03-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

2022-02-16 - 2026-12-31

Others

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-02-01 - 2028-01-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting6Sites

Recruiting4Sites

2006-10-18 - 2008-06-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2022-07-06 - 2025-05-31

Others

Active
An Open-label Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors
  • Condition/Disease

    Endometrial Neoplasms

  • Test Drug

    Tablets Capsules

Participate Sites
6Sites

Terminated6Sites

2023-08-01 - 2028-06-30

Others

Not yet recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Platform Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma (MORPHEUS-NEO HCC)
  • Condition/Disease

    Carcinoma, Hepatocellular

  • Test Drug

    注射液劑 注射液劑 注射液劑 注射液劑

Participate Sites
5Sites

Recruiting5Sites

2019-11-01 - 2025-02-28

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2024-01-12 - 2026-09-11

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • Condition/Disease

    Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  • Test Drug

    Efruxifermin

Participate Sites
7Sites

Not yet recruiting4Sites

Recruiting2Sites

Study ended1Sites

2011-07-01 - 2013-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Study ended11Sites